MEP42008A - N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate - Google Patents
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrateInfo
- Publication number
- MEP42008A MEP42008A MEP-420/08A MEP42008A MEP42008A ME P42008 A MEP42008 A ME P42008A ME P42008 A MEP42008 A ME P42008A ME P42008 A MEP42008 A ME P42008A
- Authority
- ME
- Montenegro
- Prior art keywords
- methoxyethoxy
- bis
- ethynylphenylamino
- monohydrate
- quinazolinamine mesylate
- Prior art date
Links
- ZKHFAIQCKLXUHC-UHFFFAOYSA-N 1-[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]-2-(3-ethynylphenyl)hydrazine;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NNC1=CC=CC(C#C)=C1 ZKHFAIQCKLXUHC-UHFFFAOYSA-N 0.000 title 1
- 150000004682 monohydrates Chemical class 0.000 title 1
- PCBNMUVSOAYYIH-UHFFFAOYSA-N n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 PCBNMUVSOAYYIH-UHFFFAOYSA-N 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8344198P | 1998-04-29 | 1998-04-29 | |
| PCT/IB1999/000612 WO1999055683A1 (en) | 1998-04-29 | 1999-04-08 | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP42008A true MEP42008A (en) | 2011-02-10 |
Family
ID=22178359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-420/08A MEP42008A (en) | 1998-04-29 | 1999-04-08 | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
Country Status (41)
| Country | Link |
|---|---|
| EP (1) | EP1076652B1 (cs) |
| JP (1) | JP4652569B2 (cs) |
| KR (1) | KR100668412B1 (cs) |
| CN (2) | CN1298396A (cs) |
| AP (1) | AP1252A (cs) |
| AR (1) | AR018201A1 (cs) |
| AT (1) | ATE295839T1 (cs) |
| AU (1) | AU759691C (cs) |
| BR (1) | BR9910025A (cs) |
| CA (1) | CA2330447C (cs) |
| CO (1) | CO5060467A1 (cs) |
| CZ (1) | CZ298230B6 (cs) |
| DE (1) | DE69925366T2 (cs) |
| DZ (1) | DZ2777A1 (cs) |
| EA (1) | EA002836B1 (cs) |
| EG (1) | EG24000A (cs) |
| ES (1) | ES2238825T3 (cs) |
| GT (1) | GT199900063A (cs) |
| HN (1) | HN1999000057A (cs) |
| HU (1) | HU227569B1 (cs) |
| ID (1) | ID27198A (cs) |
| IL (1) | IL139172A0 (cs) |
| MA (1) | MA26624A1 (cs) |
| ME (1) | MEP42008A (cs) |
| MX (1) | MXPA00010610A (cs) |
| MY (1) | MY136033A (cs) |
| NO (1) | NO317301B1 (cs) |
| NZ (1) | NZ508154A (cs) |
| OA (1) | OA11769A (cs) |
| PA (1) | PA8471001A1 (cs) |
| PE (1) | PE20000441A1 (cs) |
| PL (1) | PL196940B1 (cs) |
| RS (1) | RS50081B (cs) |
| SA (1) | SA99200216B1 (cs) |
| TN (1) | TNSN99079A1 (cs) |
| TR (1) | TR200003166T2 (cs) |
| TW (1) | TWI248437B (cs) |
| UA (1) | UA60363C2 (cs) |
| UY (1) | UY26099A1 (cs) |
| WO (1) | WO1999055683A1 (cs) |
| ZA (1) | ZA992972B (cs) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| YU13200A (sh) | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
| UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| US7132427B2 (en) | 2001-06-21 | 2006-11-07 | Ariad Pharmaceuticals, Inc. | Quinazolines and uses thereof |
| US7078409B2 (en) | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
| GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
| US7148231B2 (en) * | 2003-02-17 | 2006-12-12 | Hoffmann-La Roche Inc. | [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph |
| EP2348110B1 (en) | 2003-05-30 | 2013-03-27 | OncoTherapy Science, Inc. | Process for screening a drug response in cancer patients |
| KR100753385B1 (ko) | 2003-06-10 | 2007-08-30 | 에프. 호프만-라 로슈 아게 | 1,3,4-트리아자-페날린 및 1,3,4,6-테트라아자페날린유도체 |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| BRPI0510717B8 (pt) | 2004-05-06 | 2021-05-25 | Bioresponse Llc | uso de 3,3' diindolilmetano (dim) ou 2-(indol-3-ilmetil)-3,3´-diindolilmetano (ltr) |
| CA2593084C (en) | 2004-12-30 | 2014-03-18 | Bioresponse, Llc | Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions |
| WO2008012105A1 (en) | 2006-07-28 | 2008-01-31 | Synthon B.V. | Crystalline erlotinib |
| US8586621B2 (en) | 2006-10-27 | 2013-11-19 | Michael A. Zeligs | Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles |
| CA2682013C (en) * | 2007-04-04 | 2015-06-30 | Cipla Limited | Process for preparation of erlotinib and its pharmaceutically acceptable salts |
| WO2009007984A2 (en) | 2007-07-11 | 2009-01-15 | Hetero Drugs Limited | An improved process for erlotinib hydrochloride |
| US20100136116A1 (en) | 2007-08-17 | 2010-06-03 | Hetero Drugs Limited | Novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b |
| KR101132937B1 (ko) * | 2008-10-01 | 2012-04-06 | 주식회사종근당 | Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염 |
| CN102438995B (zh) | 2009-03-26 | 2014-12-17 | 兰贝克赛实验室有限公司 | 厄洛替尼或其药学上可接受的盐的制备工艺 |
| WO2011068404A2 (en) | 2009-12-02 | 2011-06-09 | Ultimorphix Technologies B.V. | Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation |
| DE202010006543U1 (de) | 2010-05-07 | 2010-09-09 | Ratiopharm Gmbh | Erlotinibresinat |
| HU230483B1 (hu) | 2011-10-10 | 2016-07-28 | Egis Gyógyszergyár Nyrt. | Erlotinib sók |
| US9593083B2 (en) | 2012-09-04 | 2017-03-14 | Shilpa Medicare Limited | Crystalline erlotinib hydrochloride process |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ243082A (en) * | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| JP2994165B2 (ja) * | 1992-06-26 | 1999-12-27 | ゼネカ・リミテッド | キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤 |
| GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| WO1996030347A1 (en) * | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
-
1999
- 1999-04-08 CA CA002330447A patent/CA2330447C/en not_active Expired - Lifetime
- 1999-04-08 DE DE69925366T patent/DE69925366T2/de not_active Expired - Lifetime
- 1999-04-08 HU HU0101818A patent/HU227569B1/hu unknown
- 1999-04-08 ID IDW20002186A patent/ID27198A/id unknown
- 1999-04-08 AU AU28509/99A patent/AU759691C/en not_active Expired
- 1999-04-08 CZ CZ20003974A patent/CZ298230B6/cs not_active IP Right Cessation
- 1999-04-08 EP EP99909165A patent/EP1076652B1/en not_active Expired - Lifetime
- 1999-04-08 CN CN99805497A patent/CN1298396A/zh active Pending
- 1999-04-08 PL PL343766A patent/PL196940B1/pl not_active IP Right Cessation
- 1999-04-08 WO PCT/IB1999/000612 patent/WO1999055683A1/en active IP Right Grant
- 1999-04-08 KR KR1020007011998A patent/KR100668412B1/ko not_active Expired - Lifetime
- 1999-04-08 RS YUP-661/00A patent/RS50081B/sr unknown
- 1999-04-08 TR TR2000/03166T patent/TR200003166T2/xx unknown
- 1999-04-08 AT AT99909165T patent/ATE295839T1/de not_active IP Right Cessation
- 1999-04-08 MX MXPA00010610A patent/MXPA00010610A/es active IP Right Grant
- 1999-04-08 JP JP2000545843A patent/JP4652569B2/ja not_active Expired - Lifetime
- 1999-04-08 NZ NZ508154A patent/NZ508154A/en not_active IP Right Cessation
- 1999-04-08 ME MEP-420/08A patent/MEP42008A/xx unknown
- 1999-04-08 CN CNA2008100051101A patent/CN101219999A/zh active Pending
- 1999-04-08 ES ES99909165T patent/ES2238825T3/es not_active Expired - Lifetime
- 1999-04-08 BR BR9910025-8A patent/BR9910025A/pt not_active Application Discontinuation
- 1999-04-08 EA EA200001112A patent/EA002836B1/ru not_active IP Right Cessation
- 1999-04-08 OA OA1200000300A patent/OA11769A/en unknown
- 1999-04-08 IL IL13917299A patent/IL139172A0/xx not_active IP Right Cessation
- 1999-04-23 TW TW088106555A patent/TWI248437B/zh not_active IP Right Cessation
- 1999-04-26 HN HN1999000057A patent/HN1999000057A/es unknown
- 1999-04-27 AR ARP990101942A patent/AR018201A1/es active IP Right Grant
- 1999-04-27 PA PA19998471001A patent/PA8471001A1/es unknown
- 1999-04-27 MY MYPI99001636A patent/MY136033A/en unknown
- 1999-04-28 MA MA25557A patent/MA26624A1/fr unknown
- 1999-04-28 TN TNTNSN99079A patent/TNSN99079A1/fr unknown
- 1999-04-28 ZA ZA9902972A patent/ZA992972B/xx unknown
- 1999-04-28 DZ DZ990077A patent/DZ2777A1/xx active
- 1999-04-29 CO CO99026003A patent/CO5060467A1/es unknown
- 1999-04-29 AP APAP/P/1999/001523A patent/AP1252A/en active
- 1999-04-29 PE PE1999000356A patent/PE20000441A1/es not_active Application Discontinuation
- 1999-04-29 GT GT199900063A patent/GT199900063A/es unknown
- 1999-04-29 EG EG48299A patent/EG24000A/xx active
- 1999-06-02 SA SA99200216A patent/SA99200216B1/ar unknown
- 1999-08-04 UA UA2000116681A patent/UA60363C2/uk unknown
-
2000
- 2000-04-05 UY UY26099A patent/UY26099A1/es not_active Application Discontinuation
- 2000-10-27 NO NO20005453A patent/NO317301B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MEP42008A (en) | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate | |
| MY129348A (en) | Stable polymorph of n-(3-ethynylphenyl)-6, 7-bis (2-methoxyethoxy)-4- quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof | |
| UY27742A1 (es) | Derivados de quinazolina | |
| BR0116452A (pt) | Composto, composição farmacêutica, uso de um composto | |
| MEP25408A (en) | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | |
| BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
| PT1274687E (pt) | Derivados de 1,2,3,4-tetra-hidroisoquinolina | |
| PL406680A1 (pl) | Inhibitory kinaz tyrozynowych | |
| NO20034230D0 (no) | 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister | |
| ATE240940T1 (de) | Arylsulfonanilid-harnstoffe | |
| SE0102315D0 (sv) | Compounds | |
| DE60118003D1 (de) | Harnstoffderivate und ihre verwendung | |
| ATE345133T1 (de) | Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin | |
| CO5601019A2 (es) | Polimorfo del clohidrato de la [6,7-bis(2-metoxi-etoxi)-quinazolin-4-il]-(3-etinil-fenil) amina | |
| UY28519A1 (es) | Derivados de quinazolina | |
| BR0209440A (pt) | Sulfonamidas | |
| DE69911023D1 (de) | Antagonisten des gonadotropin freisetzenden hormons | |
| NO20030772L (no) | Fremgangsmate til fremstilling av vannfritt azitromycin | |
| PT1060175E (pt) | Inibidores de triptase | |
| UY26426A1 (es) | Nuevos compuestos | |
| ATE279923T1 (de) | Urotensin-ii rezeptorantagonisten | |
| YU87501A (sh) | Farmaceutski kompleksi | |
| PT1411956E (pt) | Utilizacao de polissacaridos sobre-sulfatados como inibidores de vih | |
| BR0207451A (pt) | Derivados de quinolina, isoquinolina e ftalazina como antagonistas do hormÈnio liberador de gonadotropina | |
| ECSP992936A (es) | Mesilato de n-(3- etinilfenilamino) -6,7- bis (2- metoxietoxi) -4- quinazolinamina anhidro y monohidratado |